E-MAIL UPDATES

Click here to join
our Electronic Communications.

ASX Small and Mid-Cap Virtual Conference – Presentation

Interview with 180 Markets, 26 August 2020 - 180 Markets Speaks with Immutep CEO Marc Voigt about their LAG-3 Cancer treatment

Immutep CEO presentation BIO Asia-Taiwan, July 2020

Finance News Network Interview, 22. June 2020, Immutep (ASX:IMM) CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer (MBC), its global leadership under Chief Scientist and Medical Officer, Professor Frederic Triebel, and the growing interest by big pharma in immuno-therapies.

CommSec Executive Series, 9 Mar 2020, Immutep Limited (ASX:IMM) CEO, Marc Voigt

Bell Direct, 12 Mar. 2020, From the helm: Poised for a breakthrough - Immutep CEO Marc Voigt

Finance News Network Interview, 11. Mar. 2020, Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.

Speaking at the recent JP Morgan Healthcare Conference 2020, Immutep Limited (ASX:IMM)

Finance News Network Interview, 5. Nov. 2019, Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.

Finance News Network Interview, 2. Jul. 2019, Immutep Limited (ASX:IMM) CEO & Executive Director, Marc Voigt, provides an update on the company's clinical trials, including its Phase IIb AIPAC study into metastatic breast cancer.

Finance News Network Interview, March 2019, Immutep (ASX:IMM) CEO, Marc Voigt provides an update on its clinical trials, collaboration with large pharma and what they have planned for 2019

Finance News Network Interview, 12. Nov. 2018, Immutep Limited (ASX:IMM) Executive Director and CEO, Marc Voigt provides an update on the company's clinical trials, collaboration with large pharma and key milestones.

Your Money - Interview with Marc Voigt (Executive Director and CEO), 31. Oct. 2018

Finance News Network - Interview with Marc Voigt (Executive Director and CEO), 06. Sept. 2018

Brand movie - bringing new hope to patients

FNN – Interview with Immutep

Sky Business News - Interview with Marc Voigt (Executive Director and CEO), 30. April 18

Interview with Frédéric Triebel /CSO & CMO) & Marc Voigt (Executive Director and CEO)

CNBC - Interview with Marc Voigt (Executive Director and CEO)

Mode of Action of eftilagimod alpha (“IMP321”)

Sky Business News - Interview with Marc Voigt (Executive Director and CEO), 25. Nov. 15

The Business - Interview with Lucy Turnbull

Interview with 180 Markets, 26 August 2020 - 180 Markets Speaks with Immutep CEO Marc Voigt about their LAG-3 Cancer treatment

Immutep CEO presentation BIO Asia-Taiwan, July 2020

Finance News Network Interview, 22. June 2020, Immutep (ASX:IMM) CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer (MBC), its global leadership under Chief Scientist and Medical Officer, Professor Frederic Triebel, and the growing interest by big pharma in immuno-therapies.

CommSec Executive Series, 9 Mar 2020, Immutep Limited (ASX:IMM) CEO, Marc Voigt

Bell Direct, 12 Mar. 2020, From the helm: Poised for a breakthrough - Immutep CEO Marc Voigt

Finance News Network Interview, 11. Mar. 2020, Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.

Speaking at the recent JP Morgan Healthcare Conference 2020, Immutep Limited (ASX:IMM)

Finance News Network Interview, 5. Nov. 2019, Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.

Finance News Network Interview, 2. Jul. 2019, Immutep Limited (ASX:IMM) CEO & Executive Director, Marc Voigt, provides an update on the company's clinical trials, including its Phase IIb AIPAC study into metastatic breast cancer.

Finance News Network Interview, March 2019, Immutep (ASX:IMM) CEO, Marc Voigt provides an update on its clinical trials, collaboration with large pharma and what they have planned for 2019

Finance News Network Interview, 12. Nov. 2018, Immutep Limited (ASX:IMM) Executive Director and CEO, Marc Voigt provides an update on the company's clinical trials, collaboration with large pharma and key milestones.

Your Money - Interview with Marc Voigt (Executive Director and CEO), 31. Oct. 2018

Finance News Network - Interview with Marc Voigt (Executive Director and CEO), 06. Sept. 2018

Brand movie - bringing new hope to patients

FNN – Interview with Immutep

Sky Business News - Interview with Marc Voigt (Executive Director and CEO), 30. April 18

Interview with Frédéric Triebel /CSO & CMO) & Marc Voigt (Executive Director and CEO)

CNBC - Interview with Marc Voigt (Executive Director and CEO)

Mode of Action of eftilagimod alpha (“IMP321”)

Sky Business News - Interview with Marc Voigt (Executive Director and CEO), 25. Nov. 15

The Business - Interview with Lucy Turnbull

Webcasts

Give it a listen.

Wednesday, June 26th, 2019

Listen to a replay of the Immutep “KOL Call on Novel IO Therapy (eftilagimod alpha)” that took place on Wednesday, June 26, 2019

Tuesday, April 2nd, 2019

Listen to the webcast:  Update on Eftilagimod Alpha (IMP321)

Tuesday, March 26, 2019

Listen to the webcast and view the presentation "Immutep IMP761 Preclinical Results in Autoimmune Disease"

March, 19th, 2019

Listen to the webcast  “Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference”

Click here for the Presentation at Oppenheimer's 29th Annual Healthcare Conference (related to webcast)

September 7th, 2018

Immutep Newsmakers Presentation

May 29th/ 30th May

Immutep (ASX:IMM) Presentation, Clinical Results of Ongoing Melanoma Study and Update on Eftilagimod Alpha Clinical Development Strategy, May 2018